References
- Lopes G, Vulto AG, Wilking N, et al. Potential solutions for sustaining the costs of cancer drugs. Eur Oncol Haematol. 2017;13(2):102–107.
- European Medicines Agency. Biosimilar medicines. 2020.[accessed 2020 June 29]. Available from: https://www.ema.europa.eu/en/medicines/field_ema_web_categories%253Aname_field/Human/ema_group_types/ema_medicine/field_ema_med_status/authorised-36/ema_medicine_types/field_ema_med_biosimilar/search_api_aggregation_ema_medicine_types/field_ema_med_biosim
- Cazap E, Jacobs I, McBride A, et al. Global acceptance of biosimilars: importance of regulatory consistency, education, and trust. Oncologist. 2018 Oct;23(10):1188–1198. PubMed PMID: 29769386; PubMed Central PMCID: PMCPMC6263136.
- Zinzani PL, Dreyling M, Gradishar W, et al. Are biosimilars the future of oncology and haematology? Drugs. 2019 Oct;79(15):1609–1624. PubMed PMID: 31541401.
- Abraham I, Han L, Sun D, et al. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries. Future Oncol. 2014;10(9):1599–1609. PubMed PMID: 25145430.
- Cornes P, Krendyukov A. The evolution of value with filgrastim in oncology. Future Oncol. 2019 May;15(13):1525–1533. PubMed PMID: 30835142.
- Despiégel N, Cirillo L, Gaikwad I. Cost-minimisation and five-year budget impact analysis for Mvasi (bevacizumab biosimilar) in Italy. Value Health. 2019;22:S458.
- Gulacsi L, Brodszky V, Baji P, et al. The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries. Adv Ther. 2017 May;34(5):1128–1144. PubMed PMID: 28397080; PubMed Central PMCID: PMCPMC5427122.
- Boidart A, Darveau M, Dery N, et al. Real-world budget impact of listing a biosimilar of rituximab. Can J Hosp Pharm. 2020 Jan-Feb;73(1):13–18. PubMed PMID: 32109956; PubMed Central PMCID: PMCPMC7023921.
- High Cost Drugs Subgroup Greater Manchester Medicines Management Group. Rituximab biosimilar uptake recommendation 2017. [accessed 2020 June 29]. Available from: http://gmmmg.nhs.uk/docs/guidance/HCDSG-Recommendation-rituximab-biosimilar.pdf
- Garattini L, van de Vooren K, Curto A. Cost-effectiveness of trastuzumab in metastatic breast cancer: mainly a matter of price in the EU? Health Policy. 2015 Feb;119(2):212–216. PubMed PMID: 25523144.
- Lee SM, Jung JH, Suh D, et al. Budget impact of switching to biosimilar trastuzumab (CT-P6) for the treatment of breast cancer and gastric cancer in 28 European countries. BioDrugs. 2019 Aug;33(4):423–436. PubMed PMID: 31201616.
- Solakidi A, Kougioumtzoglou I, Chatzopoulo S, et al. Budget impact of trastuzumab biosimilars for the treatment of breast cancer and gastric cancer in Greece. Value Health. 2019;22:S423.
- D’Arpino A, Savoia M, Cirillo L, et al. Comparative cost analysis of subcutaneous trastuzumab originator (Herceptin) vs intravenous trastuzumab biosimilar (Kanjinti) from a hospital perspective in Italy. Value Health. 2019;22:S449.
- Agirrezabal I, Gaikwad I, Cirillo L, et al. Predicted treatment costs and savings per patient of Kanjinti (trastuzumab biosimilar) vs. subcutaneous (SC) and intravenous (IV) Herceptin and other trastuzumab biosimilars in Italy. Value Health. 2018;21:S31–S32.
- Jang Y, Byrne A, Toron F, et al. Budget impact analysis of intravenous biosimilars compared with intravenous originators and subcutaneous products. Value Health. 2018;21:S312.